Back to Journals » Journal of Hepatocellular Carcinoma » Volume 3

GPC-3 in hepatocellular carcinoma: current perspectives

Authors Wu Y, Liu H, Ding H

Received 5 July 2016

Accepted for publication 30 August 2016

Published 8 November 2016 Volume 2016:3 Pages 63—67


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Ravi Murthy

Yongle Wu,1 Hui Liu,2 Huiguo Ding1

1Department of Gastroenterology and Hepatology, 2Department of Pathology, Beijing You’an Hospital, Affiliated with Capital Medical University, Beijing, People’s Republic of China

Abstract: Glypican-3 (GPC3), a member of heparan sulfate proteoglycans, attaches to the cell membrane and is frequently observed to be elevated in hepatocellular carcinoma (HCC). However, GPC3 is not detected in normal liver tissues and benign liver lesions. Consequently, GPC3 is currently being used as a diagnostic biomarker and HCC-specific positron emission computed tomography probe to identify HCCs in normal liver tissues and benign liver lesions. The overexpression of GPC-3 in serum or liver tissue also predicts poor prognosis for HCC patients. In addition, GPC3 promotes HCC growth and metastasis by activating the canonical Wnt and other signaling pathways. Targeting of GPC3, including GC33, HN3 and YP7, might offer new immunotherapeutic tools for HCC treatment.

Keywords: glypican-3, hepatocellular carcinoma, diagnostics, prognosis, immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]